Drug Database
Back to search

Netherlands· NL-28ea40c2e0be

Qarziba 4.5 mg/ml, concentraat voor oplossing voor infusie

A dinutuximab beta product containing dinutuximab beta, registered in Netherlands by EUSA Pharma (Netherlands) B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC L01FX06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedQarziba 4.5 mg/ml, concentraat voor o…ATCL01FX06REGISTER NO.NL-28ea40c2e0bePACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dinutuximab betaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dinutuximab beta is registered in 11 of 19 countries.

Countries holding a registration under ATC L01FX06 (dinutuximab beta), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search dinutuximab beta products by name

Dinutuximab beta · ATC L01FX06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DINUTUXIMAB BETA
Manufacturer
EUSA Pharma (Netherlands) B.V.
Country
Netherlands (NL)
ATC code
L01FX06
ATC class
Dinutuximab beta
Defined daily dose
2.6 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/17/1191

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

183 interactions on record for dinutuximab beta.

Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dinutuximab beta against other medicinesHow interaction checks work

Dinutuximab beta · interactions on record

183 records

  • 54 severe
  • 129 moderate

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dinutuximab beta in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dinutuximab beta products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Qarziba
  • Liechtenstein · Qarziba
  • Norway · Qarziba

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/32e1149f-9b9c-4fed-b944-fa7da3679424
GET /v1/drugs/32e1149f-9b9c-4fed-b944-fa7da3679424?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Dinutuximab beta",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp117420",
  "excipients": [
    "HISTIDINE, (L-)",
    "POLYSORBAAT 20 (E 432)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "DINUTUXIMAB BETA"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/05/08",
  "procedure_number": "EMEA/H/C/003918",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1191",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about dinutuximab beta.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console